A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 & S9346)

C Tangen;M Hussain;C Higano;M Eisenberger;E Small;G Wilding;B Donnelly;PM Venner;P Schellhammer;ED Crawford;N Vogelzang;I Powell;IM Thompson Journal of Urology 188(4):1164-1169;

PMid: PMID22921015 | PMC number: PMC3481164

Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (PCa): better efficacy or stage migration? Data from SWOG: S9346 and 8894

M Hussain;C Tangen;CS Higano;M Eisenberger;EJ Small;G Wilding;BJ Donnelly;D McLeod;ED Crawford;IM Thompson Proceedings of the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium, abst. 30; poster

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain Therapeutic Advances in Medical Oncology 1(2):69-77;

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916 [PMID17868721]

RB Montgomery;B Goldman;CM Tangen;M Hussain;DP Petrylak;S Page;EA Klein;ED Crawford Journal of Urology 178(5):1946-1951

Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894

TM Beer;BH Goldman;CM Tangen;LB Bland;M Hussain;TG DeLoughery;ED Crawford Proc of the AUA, Journal of Urology 175(4) Suppl:385-386, (#1197)

The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894

TM Beer;CM Tangen;L Bland;M Hussain;BH Goldman;TG DeLoughery;ED Crawford Cancer 107(3):489-496

Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894

TM Beer;CM Tangen;LB Bland;IM Thompson;ED Crawford Journal of Urology 171(6, part 1 of 2):2213-2217

Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894

LB Bland;CM Tangen;IM Thompson;ED Crawford;TM Beer Proc of the American Society of Clinical Oncology 23:399 (#4574)

Ten-year survival in patients with metastatic prostate cancer

CM Tangen;J Faulkner;ED Crawford;IM Thompson;D Hirano;M Eisenberger;M Hussain Clinical Prostate Cancer 2(1):41-45

Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning

TR Glass;CM Tangen;ED Crawford;I Thompson Journal of Urology 169:164-169

Ten-year survival in patients with metastatic (M+) prostate cancer (CAP): analysis of Southwest Oncology Group (SWOG) 8894.

ED Crawford;J Faulkner;IM Thompson;M Eisenberger;C Tangen;M Hussain Journal of Urology 167(4)Suppl:304(#1202)

Impact of previous local treatment for prostate cancer on subsequent metastatic disease

IM Thompson;C Tangen;J Basler;ED Crawford Journal of Urology 168:1008-1012

Ten-year survival in patients wtih metastatic (M+) prostate cancer (CaP) analysis of Southwest Oncology Group (SWOG) 8894.

C Tangen;ED Crawford;J Faulkner;I Thompson;M Eisenberger;M Hussain Proc of the American Society of Clinical Oncology 21:188a(#749)

The relationship of gleason sum and survival in patients with metastatic (M+) prostate cancer (CaP): analysis of SWOG 8894.

ED Crawford;G Miller;J Faulkner;C Tangen;IM Thompson;M Eisenberger;M Hussain South Central Section of the AUA, 81st Annual Meetings :170(#31)

Association of African American ethnic background with survival in men with metastatic prostate cancer.

IM Thompson;CM Tangen;A Tolcher;ED Crawford;M Eisenberger;CM Moinpour Journal of the National Cancer Institute 93(3):219-225

Does a prior radical prostatectomy (RP) alter outcome of hormonal therapy for metastatic (M+) prostate cancer (CAP)

IM Thompson;J Basler;C Tangen;ED Crawford Journal of Urology 165(5)Suppl:168(#689)

Response to letter to the editor: RE: association of African-American ethnic background with survival in men with metastatic prostate cancer.

A Tolcher;ED Crawford;M Eisenberger;CM Moinpour Journal of the National Cancer Institute 93(15):1175

African American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer

I Thompson;A Tolcher;ED Crawford;M Eisenberger;C Tangen;E Fisher Journal of Urology 163(4):56Suppl(#242)

Prognostic value of serum PSA in patients with newly diagnosed metastatic prostate cancer

D Crawford;I Thompson;A Tolcher Journal of Urology 163(4)Suppl:259(#1149)

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

MA Eisenberger;BA Blumenstein;ED Crawford;G Miller;DG McLeod;PJ Loehrer;G Wilding;K Sears;DJ Culkin;IM Thompson Jr;AJ Bueschen;BA Lowe New England Journal of Medicine 339:1036-1042

Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (pts) with stage D2 adenocarcinoma of the prostate (CaP): Results of NCI Intergroup study 0105 (SWOG and ECOG).

ED Crawford;MA Eisenberger;DG McLeod;G Wilding;BA Blumenstein Journal of Urology 157(4):336(#1311)

A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG).

M Eisenberger;ED Crawford;D McLeod;P Loehrer;G Wilding;B Blumenstein Proc of the American Society of Clinical Oncology 16:2a(#3)

Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Results of the NCI intergroup study 0105 (SWOG and ECOG).

ED Crawford;M Eisenberger;DG McLeod;G Wilding;BA Blumenstein British Journal of Urology 80(Suppl.2):278(#1092)

The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of Intergroup study 0105

M Eisenberger;ED Crawford;D McLeod;M Hussain;P Loehrer;B Blumentstein ASCO 14:235(#613)

Overview analysis issues using combined androgen deprivation overview analysis as an example.

BA Blumenstein Urologic Oncology 1:95-100

Treatment of histologically confirmed D2 prostate cancer - a comparison of bilateral orchiectomy with or without flutamide (intergroup study 0105)

ED Crawford;MA Eisenberger;B Blumenstein;DG McLeod;DJ Culkin;AJ Bueschen;IM Thompson;BA Lowe Urology 151(5):238A(#44)

Some statistical considerations for the interpretation of trials of combined androgen therapy.

BA Blumenstein Cancer Supplement 72(12):3834-3840